| Citation: |
WANG Lei, MU Liping, YU Panpan, ZHANG Qianyu, GAO Guangren, ZHANG Jun. Application effect of evolocumab combined with levocarnitine in patients with acute ST-elevation myocardial infarction after surgery[J]. Journal of Clinical Medicine in Practice, 2024, 28(15): 76-79. DOI: 10.7619/jcmp.20240548
|
To investigate the effect of evolocumab combined with levocarnitine after emergency percutaneous coronary intervention (PCI) in patients with acute ST-segment elevation myocardial infarction (STEMI).
A total of 120 STEMI patients were selected and randomly divided into treatment group (60 cases) and control group (60 cases). The control group was given STEMI basic treatment plus levocarnitine, and the treatment group was given evolocumab on the basis of the control group. The therapeutic effectiveness, coronary artery microcirculation [B-type natriuretic peptide (BNP), left ventricular ejection fraction (LVEF)], coronary arteriole status[Thrombolysis in Myocardial Infarction (TIMI) risk score, preprotein converting enzyme subtilysin 9 (PCSK9) and low density lipoprotein cholesterol (LDL-C)] and incidence of adverse reactions were compared between the two groups before and after treatment.
After treatment, the total effective rate of treatment group was significantly higher than that of control group (P < 0.05). After treatment, BNP level in two groups was significantly lower than before treatment, and the level in the treatment group was significantly lower than that in the control group (P < 0.05); LVEF in the two groups was significantly higher than before treatment, and the treatment group was significantly higher than the control group (P < 0.05). After treatment, the TIMI risk score of the two groups was significantly decreased, and the treatment group was significantly lower than the control group (P < 0.05). The levels of PSCK9 and LDL-C in the two groups were significantly lower than before treatment, and the treatment group was significantly lower than the control group (P < 0.05). After treatment, there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).
Evolocumab combined with levocarnitine can improve cardiac function and coronary microcirculation in STEMI patients after emergency PCI, and has high safety.
| [1] |
李冰, 丁水印, 李新春, 等. 急性心肌梗死患者PCI术后血浆vaspin、periostin及Lp-PLA2水平对不良心血管事件的预测价值[J]. 广东医学, 2023, 44(4): 494-498. https://www.cnki.com.cn/Article/CJFDTOTAL-GAYX202304019.htm
|
| [2] |
梁鹏, 卫琪, 余道友. STEMI患者低血清白蛋白及不良事件的关系及其危险因素分析[J]. 中南医学科学杂志, 2023, 51(4): 568-570, 578. https://www.cnki.com.cn/Article/CJFDTOTAL-HYYY202304023.htm
|
| [3] |
崔北辰, 刘妍, 付燕, 等. 三种心电图标准对疑似ACS合并完全性左束支传导阻滞时被视为STEMI等危征的诊断价值[J]. 中国急救医学, 2023, 43(5): 370-375. doi: 10.3969/j.issn.1002-1949.2023.05.007
|
| [4] |
查爽英, 冯六六, 刘天华, 等. 早期应用替罗非班对急诊ST段抬高型心肌梗死患者经皮冠状动脉介入术后机体状况的影响[J]. 实用临床医药杂志, 2021, 25(3): 89-93. doi: 10.7619/jcmp.20201404
|
| [5] |
郭继磊, 李凤荣. 左卡尼汀对维持性血液透析慢性肾衰竭患者血管硬化及血管内皮功能的影响研究[J]. 中国医师进修杂志, 2023, 46(10): 909-913. doi: 10.3760/cma.j.cn115455-20220414-00303
|
| [6] |
郑贝贝. 依洛尤单抗在冠心病降脂治疗中的疗效与安全性[J]. 临床研究, 2023, 31(3): 103-106. https://www.cnki.com.cn/Article/CJFDTOTAL-LCYN202303030.htm
|
| [7] |
于运福, 闫继锋. 微血管性心绞痛发病机制的研究进展[J]. 心肺血管病杂志, 2020, 39(6): 743-746. doi: 10.3969/j.issn.1007-5062.2020.06.027
|
| [8] |
杨尚铭, 李首才, 耿超强, 等. 经皮冠状动脉介入术后支架内再狭窄的研究进展[J]. 中西医结合心脑血管病杂志, 2023, 21(20): 3754-3760. doi: 10.12102/j.issn.1672-1349.2023.20.013
|
| [9] |
郭海佳, 周萍. 左卡尼汀联合血液透析治疗对老年慢性肾衰竭患者肾功能、微炎症状态和毒素清除率的影响[J]. 中国老年学杂志, 2023, 43(5): 1117-1120. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLXZ202305028.htm
|
| [10] |
杨玉敏, 彭昭, 张源波. 依洛尤单抗对冠心病心绞痛患者PCSK9、sICAM-1水平的影响[J]. 广西医科大学学报, 2023, 40(8): 1390-1396. https://www.cnki.com.cn/Article/CJFDTOTAL-GXYD202308019.htm
|
| [11] |
李鹏鹏, 吕哲, 冯怡, 等. LVEF对STEMI合并non-IRA CTO患者PCI术预后的影响[J]. 中南医学科学杂志, 2023, 51(3): 433-436. https://www.cnki.com.cn/Article/CJFDTOTAL-HYYY202303027.htm
|
| [12] |
黄思壮, 高斯德, 林徐泽, 等. TIMI危险评分对ST段抬高型冠状动脉非阻塞性心肌梗死患者远期预后的预测价值[J]. 中国循环杂志, 2022, 37(11): 1091-1096. doi: 10.3969/j.issn.1000-3614.2022.11.003
|
| [13] |
申晨, 王晓丽, 赵秀峰. 前蛋白转化酶枯草溶菌素9抑制剂与阿托伐他汀联用对介入治疗急性心肌梗死术后的影响[J]. 心肺血管病杂志, 2023, 42(4): 304-308. https://www.cnki.com.cn/Article/CJFDTOTAL-XFXZ202304003.htm
|
| [14] |
敖登托娅, 王美英. 低密度脂蛋白胆固醇直接检测方法与间接计算公式[J]. 检验医学与临床, 2023, 20(17): 2578-2582. doi: 10.3969/j.issn.1672-9455.2023.17.027
|
| [15] |
李德林, 李佳睿, 李超, 等. 经皮冠状动脉介入术后高危患者适宜靶心率下的有氧运动对心功能影响的研究[J]. 中国康复医学杂志, 2023, 38(1): 57-61. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGKF202301024.htm
|
| [16] |
梁笑, 张煜, 吕静. 影响老年患者经皮冠状动脉介入术后谵妄的相关影响因素分析[J]. 老年医学与保健, 2023, 29(5): 942-946. doi: 10.3969/j.issn.1008-8296.2023.05.016
|
| [17] |
王奕丹, 代建南, 房超, 等. 吸烟对急性ST段抬高型心肌梗死的影响[J]. 中国介入心脏病学杂志, 2021, 29(1): 51-54. https://www.cnki.com.cn/Article/CJFDTOTAL-ZJXB202101013.htm
|
| [18] |
刘言香, 赵懿清, 李霞, 等. 曲美他嗪联合左卡尼汀治疗冠心病的疗效和安全性[J]. 临床合理用药, 2023, 16(7): 37-40. https://www.cnki.com.cn/Article/CJFDTOTAL-PLHY202307011.htm
|
| [19] |
赵培新, 方舒, 刘永国. 依洛尤单抗联合替格瑞洛治疗急性冠脉综合征临床观察[J]. 中国药业, 2023, 32(13): 103-106. https://www.cnki.com.cn/Article/CJFDTOTAL-YYGZ202313021.htm
|
| [20] |
刘卫永, 张莉, 杨帆. BNP、sTREM-1及Hcy检测评估心力衰竭患者左心功能作用分析[J]. 分子诊断与治疗杂志, 2023, 15(9): 1552-1555. https://www.cnki.com.cn/Article/CJFDTOTAL-YXYQ202309019.htm
|
| [21] |
汤曾耀, 梅寒颖. 左西孟旦联合卡维地洛治疗对心力衰竭患者临床疗效及LVEF、BNP水平的影响[J]. 中国现代医生, 2022, 60(1): 4-7. https://www.cnki.com.cn/Article/CJFDTOTAL-ZDYS202201003.htm
|
| [22] |
薛静, 孟少华, 薛云. aVL导联T波改变与TIMI危险评分对急性冠脉综合征病人心血管终点事件的预测价值[J]. 中西医结合心脑血管病杂志, 2022, 20(19): 3606-3609. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYY202219026.htm
|
| [23] |
龚乙洪, 覃润, 陈璐, 等. 前蛋白转化酶枯草溶菌素9抑制剂在冠心病中的研究进展[J]. 中国医药, 2023, 18(5): 778-781. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYG202305031.htm
|
| [24] |
车惠英, 曲琳卓, 关宏锏. 大脑中动脉穿支供血区单发脑梗死CISS临床分型及LDL-C、超敏-C反应蛋白的关系[J]. 中风与神经疾病杂志, 2019, 36(2): 140-142. https://www.cnki.com.cn/Article/CJFDTOTAL-ZFSJ201902011.htm
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: